In this study:
Lower baseline 24-hour ambulatory blood pressure measurements, as well as low systolic blood pressure during follow-up, were associated significantly with faster rates of glaucomatous visual field loss progression and may be used as a predictor of risk of glaucomatous progression.
In this study:
"Over 5 years, the continued 0.05% atropine treatment demonstrated good efficacy for myopia control. Most children needed to restart treatment after atropine cessation at year 3. Restarted treatment with 0.05% atropine achieved similar efficacy as continued treatment. Children should be considered for re-treatment if myopia progresses after treatment cessation."
.05% performed better than .025% and .01%.
This study concludes:
"Although IPL probably results in a clinically relevant reduction in symptoms of dry eyes when compared to placebo, in practice IPL would typically be used as an add-on to standard treatment. It is therefore essential with further studies investigating whether this use would give a clinically relevant reduction in symptoms, and what the potential harm of IPL is when treating MGD."
According to this study:
Treatment with Vyzulta reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved retinal vessel density. Therefore, Vyzulta likely increases macular microcirculation, possibly via nitric oxide, independent of its IOP-reducing effect.
Review of Optometry creates a summary of 80+ landmark eye studies. This is a great place to review those studies.
A new study in Ophthalmology found that there was an elevated risk of uveitis among patients who vape.
The results showed that e-cigarette users demonstrated a heightened risk of developing uveitis when compared to non-users.
Traditional cigarette use was also found to increase uveitis risk, but not as significantly as e-cigarette use.
This is an excellent review of the use of topical Losartan to minimize corneal scarring in conditions that cause corneal damage. It is not yet available but can be formulated.
This study in the American Journal of Ophthalmology concludes:
In this African ancestry cohort, low BMI was associated with increased POAG risk. POAG cases with low BMI were more likely to have larger cup-to-disc ratios, worse visual acuity, and faster functional progression, indicating more severe glaucoma.
This report on a study demonstrates that there is a slight increase (3% ) in non arteritic ischemic optic neuropathy in patients receiving semiglutide injections. The increase is slightly higher in males than females.
This is a report on a study that suggests that increased vitamin D levels, such as that associated with increased sun exposure, may be correlated with increased risk for macular degeneration.
The researchers found that among patients aged 50 and up, supplement use was associated with lower rates of developing or AMD or progressing AMD when compared with age- and sex-matched patients with no history of supplement use. Tumeric is mentioned in the title of this report.
From Review of Optometry:
Researchers in Taiwan designed a nationwide large study to investigate the association between
Alzheimer's Disease (AD) and different classes of topical glaucoma medications. They determined that using topical alpha-2 adrenergic agonists should be undertaken judiciously, especially in middle-aged and older populations. Their findings also indicated glaucoma may increase the risk of AD regardless of glaucoma subtype.“Our observations indicating that alpha-2 adrenergic agonists potentially confer an increased risk of developing AD when compared to beta-blockers
Irrespective of the type of glaucoma, individuals with glaucoma had a significantly higher risk of AD compared with those without glaucoma.
“Eyecare practitioners and neurologists need to be aware of the potentially higher risk of AD development associated with alpha-2 adrenergic agonists compared with beta-blockers among glaucoma patients,” they concluded in their paper for the journal.
“Good cholesterol” has been praised for its association with reduced cardiovascular disease risk, but new evidence suggests that elevated levels of this high-density lipoprotein cholesterol (HDL-C) may be harmful to the central nervous system. Serum lipid studies have reported associations between HDL-C and increased risk of dementia, and other associations with IOP and glaucoma have also been reported.
the study revealed an association between HDL-C levels and neurodegenerative diseases, suggesting that elevated HDL-C may serve as a novel risk factor for conditions such as dementia."
